Martin C. Münchbach
Director/Board Member chez YPSOMED HOLDING AG
Fortune : 160 098 $ au 31/03/2024
Profil
Martin C.
Münchbach is currently serving as the Director at Tioga Pharmaceuticals, Inc. since 2005, Independent Director at Ypsomed Holding AG since 2019, Director at BioVascular, Inc., Director at binx health, inc., Managing Director at BB Biotech Ventures since 2004, Director at Binx Health Ltd.
since 2011, Director at Alentis Therapeutics AG, Non-Executive Director at Ariceum Therapeutics GmbH since 2021, Partner at Biotech Ventures GP Ltd., Senior Investment Advisor at Bellevue Asset Management (Venture Capital) since 2004, and Managing Partner at Pureos Partners AG since 2017.
Previously, Dr. Münchbach held the position of Independent Director at Radius Health, Inc. from 2012 to 2015, Director at Optimer Pharmaceuticals LLC from 2005 to 2008, and various directorial roles at Molecular Partners AG, Opsona Therapeutics Ltd., Sonetik AG, and Sanofi-Synthélabo SA. He also worked as an Investment Manager at New Medical Technologies AG from 2000 to 2003 and served as a Partner at BioMedInvest AG I.Dr. Münchbach obtained his graduate and doctorate degrees from the Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
YPSOMED HOLDING AG
0,00% | 31/03/2023 | 400 ( 0,00% ) | 160 098 $ | 31/03/2024 |
Postes actifs de Martin C. Münchbach
| Sociétés | Poste | Début |
|---|---|---|
| YPSOMED HOLDING AG | Director/Board Member | 01/01/2019 |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The private company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Director/Board Member | 19/07/2011 |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | 01/01/2017 |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
| BB Biotech Ventures | Chief Executive Officer | 01/01/2004 |
Biotech Ventures GP Ltd.
 Biotech Ventures GP Ltd. Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The private company is based in St. Peter Port, UK. | Corporate Officer/Principal | - |
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Director/Board Member | - |
Tioga Pharmaceuticals, Inc.
 Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Director/Board Member | 01/01/2005 |
Bellevue Asset Management (Venture Capital)
 Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Private Equity Investor | 01/01/2004 |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Martin C. Münchbach
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Martin C. Münchbach
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| YPSOMED HOLDING AG | Health Technology |
| MOLECULAR PARTNERS AG | Health Technology |
| Entreprise privées | 17 |
|---|---|
| Sanofi-Synthélabo SA | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Health Technology |
| New Medical Technologies AG | Finance |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
BioMedInvest AG I
 BioMedInvest AG I Investment ManagersFinance BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million. | Finance |
Biotech Ventures GP Ltd.
Biotech Ventures GP Ltd. Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The private company is based in St. Peter Port, UK. | Finance |
BioVascular, Inc.
 BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Health Technology |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Technology Services |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Finance |
Sonetik AG
 Sonetik AG Medical SpecialtiesHealth Technology Sonetik AG develops and markets digital hearing aids. The firm specializes in the manufacture and distribution of medical aid devices and devices for individuals with hearing impairment or moderate hearing loss. It focuses on the integration of sound processing technologies, such as adaptive directionality, speech recognition, noise reduction, and feedback cancellation. The company was founded by Christian Stromsted in 2007 and is headquartered in Zurich, Switzerland. | Health Technology |
| BB Biotech Ventures | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
Binx Health Ltd.
Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The private company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Commercial Services |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |
